RCT: Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer.
3 May, 2022 | 10:38h | UTC
Commentary on Twitter
? #JCO #ClinicalTrialUpdate: ARCHES trial – ? Enzalutamide + ADT improved OS in men with metastatic horomone-sensitive #ProstateCancer ? https://t.co/FQ1lViCTZz #PCSM @AarmstrongDuke pic.twitter.com/fLs6PdFYlr
— Journal of Clinical Oncology (@JCO_ASCO) April 27, 2022